VectorY Therapeutics, a leader in vectorized antibody therapies for neurodegenerative diseases, announced today that the U.S.
Typically, the goal of ALS treatments is to slow the disease or halt progression. But new data from the antisense oligonucleotide (ASO) jacifusen for FUS-ALS show that two patients went beyond the ...
The Fresh Toast - the latest on medical cannabis and ALS explores symptoms, research, patient relief options, and emerging ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback